• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virus Res . Mouthrinses against SARS-CoV-2 - high antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized p

tetano

Editor, Senior Moderator
Virus Res


. 2022 Apr 30;198791.
doi: 10.1016/j.virusres.2022.198791. Online ahead of print.
Mouthrinses against SARS-CoV-2 - high antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial


Toni Luise Meister[SUP] 1 [/SUP], Josef-Maximilian Gottsauner[SUP] 2 [/SUP], Barbara Schmidt[SUP] 3 [/SUP], Natalie Heinen[SUP] 1 [/SUP], Daniel Todt[SUP] 4 [/SUP], Franz Audebert[SUP] 5 [/SUP], Felix Buder[SUP] 3 [/SUP], Henriette Lang[SUP] 5 [/SUP], André Gessner[SUP] 3 [/SUP], Eike Steinmann[SUP] 1 [/SUP], Veronika Vielsmeier[SUP] 6 [/SUP], Stephanie Pfaender[SUP] 1 [/SUP], Fabian Cieplik[SUP] 7 [/SUP]



Affiliations

Abstract

The emergence of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) represents an unprecedented threat for the human population, necessitating rapid and effective intervention measures. Given the main infection route by airborne transmission, significant attention has been bestowed upon the use of antiseptic mouthrinses as a way to possibly reduce infectious viral titers. However, clinical evaluations are still sparse. Thus, we evaluated a wide variety of antiseptic agents that can be used as mouthrinses for their antiviral effects in vitro and their respective mode of action. One of the most promising antiseptic agents (benzalkoniumchloride, BAC) was used in a randomized placebo-controlled clinical trial with subsequent analysis of viral loads by RT-qPCR and virus rescue in cell culture. Mechanistic analysis revealed that treatment with BAC and other antiseptic agents efficiently inactivated SARS-CoV-2 in vitro by primarily disrupting the viral envelope, without affecting viral RNA integrity. However, the clinical application only resulted in a mild reduction of viral loads in the oral cavity. These results indicate that gargling with mouthrinses comprising single antiseptic agents may play a minor role towards a potential reduction of transmission rates and thus, these findings are of utmost importance when considering alternative COVID-19 prevention strategies.

Keywords: SARS-CoV-2; antiseptic agents; benzalkoniumchloride; capsid protection assay; mouthrinse.
 
Back
Top Bottom